AngioSoma has a robust product pipeline, with patents, provisional patents, expired patents
with corporate intellectual property / knowledge, registered trademarks, and many more to come.
Here are the most important current corporate assets that contribute to our shareholder value.
OMNICATH I & OMNICATH II
The OmniCath I is an atherectomy catheter that helps plaque removal by drilling, pulverizing and shaving it. The OmniCath I is protected by US Patent 5,728,129, and AngioSoma, Inc. is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath™ II.
Our products have previously generated over ten million dollars ($10,000,000) in sales, through various sales outlets including GNC.
like Business Wire, but it provides the same news here in an expanded format with links to all of the initial released
locations and expanded images. This conforms to Regulation FD disclosure requirements.
AngioSoma, Inc. (OTC: SOAN) Announces Completion of Products for Market Business Wire HOUSTON — February 5, 2018 We are pleased…